BidaskClub upgraded shares of RadNet (NASDAQ:RDNT) from a hold rating to a buy rating in a research report released on Saturday.

Separately, Zacks Investment Research cut RadNet from a hold rating to a sell rating in a report on Thursday, December 6th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $15.50.

RDNT stock opened at $13.85 on Friday. The company has a debt-to-equity ratio of 4.56, a quick ratio of 1.12 and a current ratio of 1.12. RadNet has a 12-month low of $9.65 and a 12-month high of $16.54. The stock has a market capitalization of $679.29 million, a P/E ratio of 47.76, a PEG ratio of 3.35 and a beta of 1.19.

RadNet (NASDAQ:RDNT) last posted its quarterly earnings data on Friday, November 9th. The medical research company reported $0.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.15 by ($0.05). RadNet had a positive return on equity of 14.62% and a negative net margin of 0.44%. The firm had revenue of $242.10 million during the quarter, compared to analyst estimates of $240.07 million. During the same quarter in the previous year, the firm posted $0.12 earnings per share. The company’s quarterly revenue was up 6.4% on a year-over-year basis. As a group, analysts expect that RadNet will post 0.25 earnings per share for the current year.

In other news, insider Norman R. Hames sold 15,000 shares of RadNet stock in a transaction that occurred on Thursday, December 20th. The shares were sold at an average price of $10.40, for a total transaction of $156,000.00. Following the sale, the insider now owns 559,000 shares of the company’s stock, valued at approximately $5,813,600. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Norman R. Hames sold 5,000 shares of RadNet stock in a transaction that occurred on Thursday, December 13th. The shares were sold at an average price of $12.68, for a total transaction of $63,400.00. Following the sale, the insider now directly owns 569,000 shares in the company, valued at approximately $7,214,920. The disclosure for this sale can be found here. Insiders sold a total of 35,000 shares of company stock worth $407,950 over the last three months. Corporate insiders own 7.56% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in RDNT. Bank of New York Mellon Corp raised its position in RadNet by 3.4% in the second quarter. Bank of New York Mellon Corp now owns 185,216 shares of the medical research company’s stock valued at $2,778,000 after purchasing an additional 6,054 shares during the period. Schwab Charles Investment Management Inc. raised its position in RadNet by 34.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 181,304 shares of the medical research company’s stock valued at $2,720,000 after purchasing an additional 46,242 shares during the period. BlackRock Inc. raised its position in RadNet by 17.2% in the second quarter. BlackRock Inc. now owns 2,552,195 shares of the medical research company’s stock valued at $38,283,000 after purchasing an additional 374,945 shares during the period. Dimensional Fund Advisors LP raised its position in RadNet by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,560,823 shares of the medical research company’s stock valued at $23,412,000 after purchasing an additional 10,114 shares during the period. Finally, Northern Trust Corp raised its position in RadNet by 14.0% in the second quarter. Northern Trust Corp now owns 471,020 shares of the medical research company’s stock valued at $7,065,000 after purchasing an additional 57,890 shares during the period. 60.03% of the stock is currently owned by institutional investors.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Read More: Market Capitalization and Individual Investors

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.